Delivery Order SPE2DB22D2211-SPE2DB26FRHMB
- Not listed
- The Defense Logistics Agency awarded a $16,403.16 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed price, non-competitive delivery order is set to be completed by August 29, 2025, with performance executed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $7,509.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on August 19, 2025, with ultimate completion scheduled for August 20, 2025. This competitive award, placed under no set-aside designation, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,702.33 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $41,431.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. The contract, which represents a child award under AmerisourceBergen's broader pharmaceutical supply agreement with DLA, specifies performance at the contractor's Conshohocken, Pennsylvania facility with an ultimate completion date of October 23, 2025. This delivery order was awarded through open competition...
- The Defense Logistics Agency awarded a $24,402.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 21, 2025, with completion scheduled for August 22, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The award was made...
- The Defense Logistics Agency awarded a $5,103.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injections on September 22, 2025, with completion scheduled for September 23, 2025. This award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside designation, and...
- The Defense Logistics Agency (DLA) awarded a $93,571.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injectors on September 9, 2025, with completion targeted for September 10, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion prime vendor agreement designated SPE2DX and extending through December 2026. The...
- The Defense Logistics Agency awarded a $4,080.45 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on September 19, 2025, with completion scheduled for September 22, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $16,364.50 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injectors on June 2, 2025. This firm fixed-price delivery order, which is scheduled for completion by June 3, 2025, will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive delivery against AmerisourceBergen's larger pharmaceutical supply contract vehicle with the DLA. This...
- The Defense Logistics Agency awarded a $5,041.46 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This is a firm fixed price, non-set-aside contract with a completion date of June 20, 2025, and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB26FRHMBDelivery Order
The Defense Logistics Agency (DLA) awarded a $30,113.19 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injectors, with an ultimate completion date of November 3, 2025. This non-competitive delivery order was issued on October 31, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of medications and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for Department of Defense and veteran healthcare systems. The contractor maintains an extensive portfolio of federal contract awards with DLA covering diverse pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order for Zepbound, a GLP-1 receptor agonist diabetes medication, exemplifies the company's role in supplying specialized pharmaceutical commodities to support military healthcare needs through its established vendor relationship with the Defense Logistics Agency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.1k | 10/31/25 |